Tags

Type your tag names separated by a space and hit enter

Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain.
Vaccine. 2012 Oct 05; 30(45):6427-35.V

Abstract

BACKGROUND

We hypothesized that low dose intradermal vaccination of the trivalent influenza vaccine (TIV) delivered by the MicronJet600™ (NanoPass Technologies, Israel) would be non-inferior to the full dose intramuscular and mid dose Intanza(®) vaccination in the elderly and the chronically ill adults.

METHODS

We performed a prospective randomized trial on elderly and chronically ill adults. Subjects were randomly assigned into 4 groups. Groups ID3 and ID9 received reduced dose ID TIV (3 μg and 9 μg of hemagglutinin (HA) per strain respectively) delivered by MicronJet600™ (NanoPass Technologies, Israel). Group INT9 received reduced dose ID TIV (9 μg) delivered by Becton Dickinson's Soluvia™ device (Intanza(®)9, Sanofi-Pasteur, France). Control group IM15 received a full dose IM TIV (15 μg). We measured antibody titers by hemagglutination inhibition (HAI) and microneutralization (MN) assays at baseline and day 21.

RESULTS

Baseline characteristics for all groups were similar (group and sample sizes: ID3=63; ID9=68; INT9=65; and IM15=66). At day 21 post vaccination, the GMT ratio and the seroconversion rates difference for all three strains of the ID vaccine groups were non-inferior to the IM vaccine group. The seroconversion rate, seroprotection rate, and the GMT of the H1N1 strains by HAI and MN assays were significantly higher in the ID groups compared with the full dose IM vaccine group. The seroconversion rates of the H3N2 strain by HAI assay were also significantly higher in the ID groups when compared with the full dose IM group. Direct comparison among the three ID groups showed no significant differences. No serious adverse events related to vaccination were reported.

CONCLUSION

Dose-sparing ID TIV can overcome reduced immunogenicity of the H1N1 strain, and according to some measures, for the H3N2 strain. At risk subjects indicated for the TIV should be considered for intradermal immunization to compensate for reduced immunogenicity.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Hung IF
State Key Laboratory for Emerging Infectious Diseases, Carol Yu's Centre for Infection and Division of Infectious Diseases, The University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, Hong Kong. ivanfn@gmail.com
Levin Y
No affiliation info available
To KK
No affiliation info available
Chan KH
No affiliation info available
Zhang AJ
No affiliation info available
Li P
No affiliation info available
Li C
No affiliation info available
Xu T
No affiliation info available
Wong TY
No affiliation info available
Yuen KY
No affiliation info available

MeSH

AgedAntibodies, ViralFemaleHemagglutination Inhibition TestsHemagglutinin Glycoproteins, Influenza VirusHumansInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza VaccinesInfluenza, HumanInjections, IntradermalMaleNeutralization TestsProspective StudiesVaccination

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22910287

Citation

Hung, Ivan F N., et al. "Dose Sparing Intradermal Trivalent Influenza (2010/2011) Vaccination Overcomes Reduced Immunogenicity of the 2009 H1N1 Strain." Vaccine, vol. 30, no. 45, 2012, pp. 6427-35.
Hung IF, Levin Y, To KK, et al. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain. Vaccine. 2012;30(45):6427-35.
Hung, I. F., Levin, Y., To, K. K., Chan, K. H., Zhang, A. J., Li, P., Li, C., Xu, T., Wong, T. Y., & Yuen, K. Y. (2012). Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain. Vaccine, 30(45), 6427-35. https://doi.org/10.1016/j.vaccine.2012.08.014
Hung IF, et al. Dose Sparing Intradermal Trivalent Influenza (2010/2011) Vaccination Overcomes Reduced Immunogenicity of the 2009 H1N1 Strain. Vaccine. 2012 Oct 5;30(45):6427-35. PubMed PMID: 22910287.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain. AU - Hung,Ivan F N, AU - Levin,Yotam, AU - To,Kelvin K W, AU - Chan,Kwok-Hung, AU - Zhang,Anna Jinxia, AU - Li,Patrick, AU - Li,Clara, AU - Xu,Ting, AU - Wong,Tin-Yan, AU - Yuen,Kwok-Yung, Y1 - 2012/08/18/ PY - 2012/01/02/received PY - 2012/08/05/revised PY - 2012/08/08/accepted PY - 2012/8/23/entrez PY - 2012/8/23/pubmed PY - 2013/2/12/medline SP - 6427 EP - 35 JF - Vaccine JO - Vaccine VL - 30 IS - 45 N2 - BACKGROUND: We hypothesized that low dose intradermal vaccination of the trivalent influenza vaccine (TIV) delivered by the MicronJet600™ (NanoPass Technologies, Israel) would be non-inferior to the full dose intramuscular and mid dose Intanza(®) vaccination in the elderly and the chronically ill adults. METHODS: We performed a prospective randomized trial on elderly and chronically ill adults. Subjects were randomly assigned into 4 groups. Groups ID3 and ID9 received reduced dose ID TIV (3 μg and 9 μg of hemagglutinin (HA) per strain respectively) delivered by MicronJet600™ (NanoPass Technologies, Israel). Group INT9 received reduced dose ID TIV (9 μg) delivered by Becton Dickinson's Soluvia™ device (Intanza(®)9, Sanofi-Pasteur, France). Control group IM15 received a full dose IM TIV (15 μg). We measured antibody titers by hemagglutination inhibition (HAI) and microneutralization (MN) assays at baseline and day 21. RESULTS: Baseline characteristics for all groups were similar (group and sample sizes: ID3=63; ID9=68; INT9=65; and IM15=66). At day 21 post vaccination, the GMT ratio and the seroconversion rates difference for all three strains of the ID vaccine groups were non-inferior to the IM vaccine group. The seroconversion rate, seroprotection rate, and the GMT of the H1N1 strains by HAI and MN assays were significantly higher in the ID groups compared with the full dose IM vaccine group. The seroconversion rates of the H3N2 strain by HAI assay were also significantly higher in the ID groups when compared with the full dose IM group. Direct comparison among the three ID groups showed no significant differences. No serious adverse events related to vaccination were reported. CONCLUSION: Dose-sparing ID TIV can overcome reduced immunogenicity of the H1N1 strain, and according to some measures, for the H3N2 strain. At risk subjects indicated for the TIV should be considered for intradermal immunization to compensate for reduced immunogenicity. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/22910287/Dose_sparing_intradermal_trivalent_influenza__2010/2011__vaccination_overcomes_reduced_immunogenicity_of_the_2009_H1N1_strain_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(12)01193-0 DB - PRIME DP - Unbound Medicine ER -